Lipid lowering drug therapy in patients with coronary heart disease from 24 European countries – Findings from the EUROASPIRE IV survey

Abstract

Too many CHD patients with dyslipidaemia are still inadequately treated and most of these patients on statin therapy are not achieving the treatment targets. Therapeutic control of LDL-C is clearly related to the intensity of lipid lowering drug regimen after the CHD event indicating that a considerable potential still exists throughout Europe to reduce CHD mortality and morbidity rates through more efficient LDL-C lowering.

Cardiovascular Lipid Risk Factors and Rate of Cardiovascular Events After Myocardial Revascularization

“…13 Other authors suggested several reasons for the mediocre response during statin therapy: inadequate dose, non-adherence to prescribed dose, statin resistance and / or intolerance, and side effects. 14,15 However, our results confirm the association between increased LDL-c levels with cardiovascular event rates.…”

“…Reiner et al 13 emphasized the need to reduce LDL-c levels after a cardiovascular event to reduce coronary heart disease mortality and morbidity. 13 Other authors suggested several reasons for the mediocre response during statin therapy: inadequate dose, non-adherence to prescribed dose, statin resistance and / or intolerance, and side effects.…”

“…9,12,13 Despite the use of medications, patients undergoing myocardial revascularization remain at risk of cardiovascular events related to atherosclerosis progression and other metabolic diseases. 9,11 Results from the EUROASPIRE IV 6 pointed out that the Joint European Societies Guidelines on Cardiovascular Prevention recommendations are achieved in a still low proportion of coronary patients across Europe.…”

Lipid Control in Patients After Myocardial Infarction - An Effective Tool for Managing Cardiovascular Risks

“…В России этот пока-затель составил 15,9%. Наилучшие показатели продемонстрировала Испания -41% [20].…”

PCSK9 − „missing link“ der familiären Hypercholesterinämie

“…So kann trotz maximaler Statindosis und Kombination mit Hemmstoffen der enteralen Cholesterinaufnahme (Ezetimib, Ionenaustauscherharze) bei Hochrisikopatienten keine klinisch ausreichende LDL-Senkung erreicht werden [3]. Ein Grund hierfür liegt in der Variabilität des Ansprechens der Patienten auf Statine.…”